First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Michael L MaitlandJasgit C SachdevManish R SharmaVictor MorenoValentina BoniShivaani KummarErica Stringer-ReasorNehal LakhaniAllison R MoreauDawei XuanRay LiEric L PowellAmy Jackson-FisherMichelle BowersShilpa AlekarXiaohua XinAnthony W TolcherEmiliano CalvoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This PTK7-targeted ADC demonstrated therapeutic activity in previously treated patients with ovarian cancer, NSCLC, and TNBC at a dose range of 2.1-3.2 mg/kg, supporting further clinical evaluation to refine dose, schedule, and predictive tissue biomarker testing in patients with advanced malignancies.
Keyphrases
- tyrosine kinase
- clinical evaluation
- cancer therapy
- epidermal growth factor receptor
- endothelial cells
- small cell lung cancer
- advanced non small cell lung cancer
- drug delivery
- induced pluripotent stem cells
- magnetic resonance imaging
- protein protein
- binding protein
- small molecule
- amino acid
- newly diagnosed
- brain metastases